Tamsulosin Efficiency in Treatment of Benign Prostatic Hyperplasia Evaluated by Determining Bladder Weight
Snjezana Milicevic
Med Arh. 2012; 66(6): 391-395

View PDF Fulltext


Introduction/Goal: Bladder wall thickness and bladder mass are higher in patients with subvesical obstruction caused by benign prostate enlargement (BPE) in compensated stage of the disease. The goal of the study was to determine changes of bladder detrusor in patients suffering from benign prostatic hyperplasia (BPH) during tamsulosin treatment. The study was open, prospective and multi-centric. Material and methods: The material in this study was composed of 20 patients, aged > 45 years, with the present lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia, who had not been treated for the previous 3 months. The inclusive criteria also included the value of International Prostate Symptom Score (IPSS) ≥8 points, post-void residual urine volume (PVR) <100 ml and prostate specific antigen (PSA) <4 ng/ml. After the end of the trials that were necessary for the introduction of the patients in the study, the patients started taking tamsulosin in a daily dosage of 0.4 mg, and the evaluation parameters during the research were measured at time intervals of 4, 12 and 24 weeks. The evaluation parameters were primary and secondary. The primary parameter included ultrasound estimated bladder weight (UEWB), while the secondary included determination of the blood pressure values (RR) and pulse frequency (PF), of total International Prostate Symptom Score (T-IPSS), a part of IPSS that related to the storage symptoms (I-PSS), a part that related to the voiding symptoms (O-IPSS), quality of life determination (IPSS-QoL), ultrasound estimation of prostate volume (VP) and the quantity of post-void residual urine volume (PVR), along with the determination of the number and strength of adverse reactions. Results: During the introduction of the patients in the trial, the arithmetic mean of UEWB was 65 g, of PVR 43 ml, VP 35 ml, of total T-IPSS 15.6 points, of I-IPSS 6.9 points, of O-IPSS 8.7 points, and of IPSS-QoL 3.6 points. During the four-week, twelve-week and twenty-four-week checkups, the values were the following: the arithmetic mean of UEWB 36, 39 and 28 grams, of PVR 26, 29 and 21 ml, of T-IPSS 8.3, 6.4 and 5.0 points, of IPSS 3.8, 3.0 and 2.4 points, of O-IPSS 4.6, 3.4 and 2.6 points, of IPSS-QoL 1.7, 1.1 and 1.0 points and of VP 34 ml during the last control. The obtained results of this trial were processed by descriptive statistics (arithmetic mean and standard deviation) and analytical statistics by way of Student’s t-test for dependant (paired) samples, with the comparison made between the obtained results with the zero checkup and four-week checkup, and subsequently the comparison between four-week and twelve-week checkup, twelve-week and twenty-four week checkup, and the zero checkup and the twenty-four week checkup. Adverse drug reactions (libido and ejaculation problems 5% and headache 5%) were mild and tolerant and did not require the interruption of the therapy. Conclusion: During a 24-week treatment of benign prostatic hyperplasia with tamsulosin, the same showed clinical efficiency in the sense of improvement of LUTS and a decrease of bladder outlet obstruction (BOO), without the influence on prostate volume or showing statistically significant vasodilatory effect. The same affected a significant decrease of ultrasound estimated bladder weight (from 65 g to 28 g).


1. Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, retik A, Vaughan E, Wein A (eds). Campbells Urology, 8th ed. Saunders: Philadelphia, 2002. pp 1297-1336.

2. Eckhardt MD, van Venrooji GE, Boon TA. Symptoms, prostate volume and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia. Urology. 2001; 58: 966-971.

3. Roehrborn CG, Schwinn DA. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004; 171: 1029-1035.

4. Medina JJ, Parra RO, Moore RG. Benign prostatic hyperplasia (the aging prostate). Med Clin North Am. 1999; 83: 1213-1229.

5. Barry MJ. Measuring and assessing BPH in population group. In Kirby RS, McConnell JD, Fitzpatrick JM, Roehrborn CG, Boyle P. Textbook of Benign Prostatic Hyperplasia, 2nd edn. London: TaylorFrancis, 2005:141-50.

6. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D. Identification of alpha 1-adrenoreceptor subtypes present in the human prostate. Life Sci. 1994; 54: 1595-1605.

7. Lepor H, Tang R, Kobayashi S et al. Localization of the alpha 1A-adrenoreceptor in the human prostate. J Urol. 1995; 154: 2096-2099.

8. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha 1A-1, alpha 1B and alpha 1D-adrenoreceptors in hyperplastic and non-hyperplastic hum, and prostate. J Urol. 1999; 161: 635-640.

9. Miyashita H, Kojima M, Miki T. Ultrasonic measurement of bladder weight as a possible predictor of cute urinary retention in men with lower urinary tract symptoms suggestive of benign prostate hyperplasia. Ultrasound Med Biol. 2002; 28: 985-990.

10. Hakenberg OW, Linne C, Manseck A, Wirth MP. Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourol Urodyn. 2000; 19: 585-593.

11. Kojima M, Inui E, OchiaiA, Naya Y, Ukimura O, Watanabe H. Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction. Urology. 1996; 47: 942

12. Oelke M, Bachmann A, Descazeaud A, Emberton M, et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Guidelines EAU; 2012.

13. Keong TF. Decision making in the management of benign prostatic enlargement and the role of transabdominal ultrasound. IJU. 2010; 17: 974-979.

14. Manieri C, Carter SSC, Romano G, trucchi A, Valentini M, Tubaro A. The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J urol. 1998;159:761-765.

15. Kojima M, Inui E, Ochiai A, Naya Y, Ukimura O, Watanabe H. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement od bladder weight. J Urol. 1997; 157:476-479.

16. Walsh PC: Benign prostatic hyperplasia, in Walsh PC, Retic AB, Stamey TA, and Vaughan ED Jr (Eds): Capmbells Urology, 6th ed. Philadelphia, WB Saunders, 1992. pp 1007-1027

17. Oelke M, Hofner K, Wiese B, Grunewald V, Jonas U. Increase in detrusor wall thickness indicates bladder outlet obstruction (BOO) in men. World J Urol. 2002; 19: 443-452.

18. Uluocak N, erdemir F, Parlaktas BS, Caglar MK, Hasiloglu Z, Etikan I. Bladder wall thickness in healthy school-aged children. Urology. 2007; 69: 763-766.

19. Blatt AH, Titus J, Chan L. Ultrasound measurement of bladder wall thickness in the assessment of voiding dysfunction. J urol 2008;179:2275-9.

20. Lekskulchai O, Dietz HP. Detrusor wall thickness as a test for detrusor overactivity in women. Ultrasound Obstet Gynaecol. 2008; 32: 535-539.

21. Kojima M, Inui E, Ochiai A, Ukimura O, Watanabe H. Quantitative evaluation of estimated bladder weight (EWB) in men with infravesical obstruction using transabdominal sonography- a preliminary study. Neurourol. Urodyn. 1995; 14: 453.

22. Kokima Y, Sasaki S, Imura M, Kubota Y, Hayasi Y, Kohri K. Correlation between expression of alpha 1 adrenoreceptor subtype mRNA and severity of lower urinary tract symptoms or bladder outlet obstruction in benign prostatic hyperplasia patients. BJU Int. 2010; 107: 438-442.

23. Schwinn DA. The role of alpha 1 adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2001; 88: 27-34.

24. Aganovic D, Hadziosmanovic O, Prcic A, Kulovac B. The Significance of the Influence of Aging and Intravesical Obstruction Caused by Benign Prostatic Enlargement on Detrusor Impairment. Med Arh. 2012; 66(3): 185-189.

25. Aganovic D, Prcic A, Hadziosmanovic O, Hasanbegovic M. Does the Combination of Intravesical Prostatic Protrusion and Bladder Outlet Obstruction Number Increase Test Accuracy According to BenignProstatic Obstruction at the Individual Level. Acta Inform Med. 2012; 20(3): 160-166.

26. Aganovic D, Hasanbegovic M, Prcic A, Kulovac B, Hadziosmanovic O. Which is a Better Indicator of Bladder Outlet Obstruction in Patients with Benign Prostatic Enlargement – Intravesical Protrusion of Prostate or Bladder Wall Thickness? Med Arh. 2012; 66(5): 324-328.

Be the first to comment

Leave a Reply

Your email address will not be published.


Ova web-stranica koristi Akismet za zaštitu protiv spama. Saznajte kako se obrađuju podaci komentara.